Brivaracetam vs Levetiracetam (Elepsia XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Synaptic vesicle glycoprotein 2A (SV2A) · full Epilepsy pipeline
Brivaracetam
Marketed by UCB
NCT04666610 · Phase 3 · completed
The trial randomized 154 participants and used quadruple masking with placebo control, with absence-seizure freedom measured by 24-hour EEG as the primary clinical endpoint. Because the registry has no posted results, whether the primary endpoint was met is unknown, supporting a moderate evidence grade rather than a strong one.
Next expected readout: November 2029 · NCT06315322 (registry estimate)
No aligned efficacy figure on record for this race.
Levetiracetam (Elepsia XR)
Rights held by Sun Pharma Advanced Research Company Limited and partners; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Brivaracetam | Levetiracetam (Elepsia XR) |
|---|---|---|
| Seizure frequency, % change | -53.0% vs -24.4%−28.7 vs placeboNCT001758252 other results
| —Not posted · NCT05722951 |
| 50% responder rate | 36% vs 20%+16 vs placeboNCT004900357 other results
| —Not posted · NCT05722951 |
| Seizure freedom | 86.7% vs 73.3%vs Lorazepam (LZP)NCT030210185 other results
| —Not posted · NCT05722951 |
Seizure frequency, % change
- Brivaracetam
- -53.0% vs -24.4%−28.7 vs placeboNCT00175825
2 other results
- -41.6% vs -24.4% NCT00175825
- -29.9% vs -24.4% NCT00175825
- Levetiracetam (Elepsia XR)
- —Not posted · NCT05722951
50% responder rate
- Brivaracetam
- 36% vs 20%+16 vs placeboNCT00490035
7 other results
- 49.3% vs 19% NCT03083665
- 41.1% vs 19% NCT03083665
- 27.3% vs 20% NCT00490035
- 27.3% vs 20% NCT00490035
- 55.8% vs 16.7% NCT00175825
- 44.2% vs 16.7% NCT00175825
- 32% vs 16.7% NCT00175825
- Levetiracetam (Elepsia XR)
- —Not posted · NCT05722951
Seizure freedom
- Brivaracetam
- 86.7% vs 73.3%vs Lorazepam (LZP)NCT03021018
5 other results
- 80% vs 73.3% NCT03021018
- 80% vs 60% NCT03021018
- 80% vs 73.3% NCT03021018
- 80% vs 73.3% NCT03021018
- 80% vs 60% NCT03021018
- Levetiracetam (Elepsia XR)
- —Not posted · NCT05722951
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Levetiracetam (Elepsia XR): registry results are on file for Epilepsy, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Brivaracetam: 4 of 4 rows · Levetiracetam (Elepsia XR): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Brivaracetam |
|---|---|
| Dropout rate | 21.9%Childhood Absence Epilepsy (CAE): a NCT05109234 · Phase 3 · registry result, not featured evidence show 40 more results30%Juvenile Absence Epilepsy (JAE): B NCT05109234 · Phase 3 · registry result, not featured evidence 41.2%Direct Enrollers BRV NCT03250377 · Phase 3 · registry result, not featured evidence 42.9%N01379 BRV NCT03250377 · Phase 3 · registry result, not featured evidence 5.4%200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence —200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 3.3%50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence —50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 50%Age Cohort: ≥1 Month to <2 Years NCT01364597 · Phase 3 · registry result, not featured evidence 43.1%Age Cohort: ≥12 to <17 Years NCT01364597 · Phase 3 · registry result, not featured evidence 73.3%Age Cohort: ≥2 to <4 Years NCT01364597 · Phase 3 · registry result, not featured evidence 53.9%Age Cohort: ≥4 to <12 Years NCT01364597 · Phase 3 · registry result, not featured evidence — NCT00175916 · Phase 3 · registry result, not featured evidence — NCT01339559 · Phase 3 · registry result, not featured evidence 74.4% NCT00150800 · Phase 3 · registry result, not featured evidence — NCT00761774 · Phase 3 · registry result, not featured evidence —Brivaracetam Focal Epilepsy (SS) NCT01728077 · Phase 3 · registry result, not featured evidence —Brivaracetam Generalized Epilepsy NCT01728077 · Phase 3 · registry result, not featured evidence 11.4%100 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence 10.4%200 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence 10.3% NCT01653262 · Phase 3 · registry result, not featured evidence 0%Brivaracetam (BRV) Tablets / BRV B NCT01405508 · Phase 3 · registry result, not featured evidence 0%Brivaracetam (BRV) Tablets / BRV I NCT01405508 · Phase 3 · registry result, not featured evidence 6%100 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 12%50 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 6.1%20 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 8.8%50 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 7%20 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 17.2%5 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 10% NCT00504881 · Phase 3 · registry result, not featured evidence —Age Cohort: >=1 Month to <2 Years NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=12 to <16 Years (SS- NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=2 to <6 Years (SS-iv NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=6 to <12 Years (SS-i NCT03405714 · Phase 2 · registry result, not featured evidence —100 mg NCT03021018 · Phase 2 · registry result, not featured evidence —200 mg NCT03021018 · Phase 2 · registry result, not featured evidence — NCT00422422 · Phase 2 · registry result, not featured evidence 1.9%50 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 1.9%20 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 8%5 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | 3.1%Childhood Absence Epilepsy (CAE): a NCT05109234 · Phase 3 · registry result, not featured evidence show 40 more results10%Juvenile Absence Epilepsy (JAE): B NCT05109234 · Phase 3 · registry result, not featured evidence 11.8%Direct Enrollers BRV NCT03250377 · Phase 3 · registry result, not featured evidence 0%N01379 BRV NCT03250377 · Phase 3 · registry result, not featured evidence 3.4%200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence —200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 2.6%50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence —50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 11.1%Age Cohort: ≥1 Month to <2 Years NCT01364597 · Phase 3 · registry result, not featured evidence 10.8%Age Cohort: ≥12 to <17 Years NCT01364597 · Phase 3 · registry result, not featured evidence 33.3%Age Cohort: ≥2 to <4 Years NCT01364597 · Phase 3 · registry result, not featured evidence 11.3%Age Cohort: ≥4 to <12 Years NCT01364597 · Phase 3 · registry result, not featured evidence — NCT00175916 · Phase 3 · registry result, not featured evidence — NCT01339559 · Phase 3 · registry result, not featured evidence 13.3% NCT00150800 · Phase 3 · registry result, not featured evidence — NCT00761774 · Phase 3 · registry result, not featured evidence —Brivaracetam Focal Epilepsy (SS) NCT01728077 · Phase 3 · registry result, not featured evidence —Brivaracetam Generalized Epilepsy NCT01728077 · Phase 3 · registry result, not featured evidence —100 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence —200 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence — NCT01653262 · Phase 3 · registry result, not featured evidence —Brivaracetam (BRV) Tablets / BRV B NCT01405508 · Phase 3 · registry result, not featured evidence —Brivaracetam (BRV) Tablets / BRV I NCT01405508 · Phase 3 · registry result, not featured evidence 0%100 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 1%50 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 0%20 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence —50 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence —20 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence —5 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence — NCT00504881 · Phase 3 · registry result, not featured evidence —Age Cohort: >=1 Month to <2 Years NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=12 to <16 Years (SS- NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=2 to <6 Years (SS-iv NCT03405714 · Phase 2 · registry result, not featured evidence —Age Cohort: >=6 to <12 Years (SS-i NCT03405714 · Phase 2 · registry result, not featured evidence —100 mg NCT03021018 · Phase 2 · registry result, not featured evidence —200 mg NCT03021018 · Phase 2 · registry result, not featured evidence — NCT00422422 · Phase 2 · registry result, not featured evidence 1.9%50 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 1.9%20 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 4%5 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Serious AEs | 3.1%Childhood Absence Epilepsy (CAE): a NCT05109234 · Phase 3 · registry result, not featured evidence show 40 more results10%Juvenile Absence Epilepsy (JAE): B NCT05109234 · Phase 3 · registry result, not featured evidence 17.6%Direct Enrollers BRV NCT03250377 · Phase 3 · registry result, not featured evidence 71.4%N01379 BRV NCT03250377 · Phase 3 · registry result, not featured evidence 2.7%200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 2.7%200 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 1.3%50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 0%50 mg/Day NCT03083665 · Phase 3 · registry result, not featured evidence 38.9%Age Cohort: ≥1 Month to <2 Years NCT01364597 · Phase 3 · registry result, not featured evidence 29.2%Age Cohort: ≥12 to <17 Years NCT01364597 · Phase 3 · registry result, not featured evidence 53.3%Age Cohort: ≥2 to <4 Years NCT01364597 · Phase 3 · registry result, not featured evidence 29.8%Age Cohort: ≥4 to <12 Years NCT01364597 · Phase 3 · registry result, not featured evidence 29.1% NCT00175916 · Phase 3 · registry result, not featured evidence 18.3% NCT01339559 · Phase 3 · registry result, not featured evidence 22.8% NCT00150800 · Phase 3 · registry result, not featured evidence 24.1% NCT00761774 · Phase 3 · registry result, not featured evidence 26.3%Brivaracetam Focal Epilepsy (SS) NCT01728077 · Phase 3 · registry result, not featured evidence 28.6%Brivaracetam Generalized Epilepsy NCT01728077 · Phase 3 · registry result, not featured evidence 3.2%100 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence 3.2%200 mg/day NCT01261325 · Phase 3 · registry result, not featured evidence 3.4% NCT01653262 · Phase 3 · registry result, not featured evidence 0%Brivaracetam (BRV) Tablets / BRV B NCT01405508 · Phase 3 · registry result, not featured evidence 0%Brivaracetam (BRV) Tablets / BRV I NCT01405508 · Phase 3 · registry result, not featured evidence 2%100 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 4%50 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 2%20 mg/day NCT00490035 · Phase 3 · registry result, not featured evidence 4%50 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 3%20 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 1%5 mg/day NCT00464269 · Phase 3 · registry result, not featured evidence 5.6% NCT00504881 · Phase 3 · registry result, not featured evidence 7.7%Age Cohort: >=1 Month to <2 Years NCT03405714 · Phase 2 · registry result, not featured evidence 0%Age Cohort: >=12 to <16 Years (SS- NCT03405714 · Phase 2 · registry result, not featured evidence 0%Age Cohort: >=2 to <6 Years (SS-iv NCT03405714 · Phase 2 · registry result, not featured evidence 0%Age Cohort: >=6 to <12 Years (SS-i NCT03405714 · Phase 2 · registry result, not featured evidence 0%100 mg NCT03021018 · Phase 2 · registry result, not featured evidence 0%200 mg NCT03021018 · Phase 2 · registry result, not featured evidence 8.1% NCT00422422 · Phase 2 · registry result, not featured evidence 0%50 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 1.9%20 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 0%5 mg/day NCT00175825 · Phase 2 · registry result, not featured evidence 0% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | a petit mal epilepsy 14.1% pyrexia 6.3% headache 4.7% NCT05109234 · Phase 3 · registry result, not featured evidence show 40 more resultspetit mal epilepsy 25% pyrexia 20% headache 10% NCT05109234 · Phase 3 · registry result, not featured evidence corona virus infection 32.4% (placebo 24.1%) nasopharyngitis 26.5% (placebo 37%) pyrexia 17.6% (placebo 16.7%) NCT03250377 · Phase 3 · registry result, not featured evidence dizziness 42.9% (placebo 22.2%) nasopharyngitis 42.9% (placebo 37%) abdominal pain upper 28.6% (placebo 3.7%) NCT03250377 · Phase 3 · registry result, not featured evidence 200 mg/Day somnolence 18.9% (placebo 8.1%) dizziness 14.2% (placebo 4%) nasopharyngitis 6.8% (placebo 6.7%) NCT03083665 · Phase 3 · registry result, not featured evidence 200 mg/Day nasopharyngitis 5.4% (placebo 6.7%) dizziness 0% (placebo 4%) headache 0% (placebo 7.4%) NCT03083665 · Phase 3 · registry result, not featured evidence 50 mg/Day dizziness 11.3% (placebo 4%) somnolence 9.9% (placebo 8.1%) headache 7.3% (placebo 7.4%) NCT03083665 · Phase 3 · registry result, not featured evidence 50 mg/Day nasopharyngitis 5.9% (placebo 6.7%) dizziness 0% (placebo 4%) headache 0% (placebo 7.4%) NCT03083665 · Phase 3 · registry result, not featured evidence pyrexia 41.7% nasopharyngitis 30.6% vomiting 30.6% NCT01364597 · Phase 3 · registry result, not featured evidence headache 24.6% nasopharyngitis 24.6% seizure 16.9% NCT01364597 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 33.3% vomiting 33.3% nasopharyngitis 26.7% NCT01364597 · Phase 3 · registry result, not featured evidence nasopharyngitis 31.2% pharyngitis 27.7% pyrexia 26.2% NCT01364597 · Phase 3 · registry result, not featured evidence headache 21.8% nasopharyngitis 18.4% dizziness 14.4% NCT00175916 · Phase 3 · registry result, not featured evidence headache 13.3% dizziness 13.1% somnolence 9.5% NCT01339559 · Phase 3 · registry result, not featured evidence headache 24.7% dizziness 21.3% nasopharyngitis 14.1% NCT00150800 · Phase 3 · registry result, not featured evidence nasopharyngitis 17.6% depression 16.7% convulsion 15.7% NCT00761774 · Phase 3 · registry result, not featured evidence headache 36.8% back pain 15.8% convulsion 15.8% NCT01728077 · Phase 3 · registry result, not featured evidence upper respiratory tract 28.6% urinary tract infection 28.6% back pain 14.3% NCT01728077 · Phase 3 · registry result, not featured evidence 100 mg/day somnolence 19.4% (placebo 7.7%) dizziness 10.3% (placebo 5%) fatigue 7.5% (placebo 3.8%) NCT01261325 · Phase 3 · registry result, not featured evidence 200 mg/day somnolence 16.8% (placebo 7.7%) dizziness 14.4% (placebo 5%) fatigue 11.6% (placebo 3.8%) NCT01261325 · Phase 3 · registry result, not featured evidence headache 17.2% back pain 10.3% fatigue 10.3% NCT01653262 · Phase 3 · registry result, not featured evidence somnolence 25.9% (placebo 30.8%) dizziness 11.1% (placebo 15.4%) fatigue 11.1% (placebo 3.8%) NCT01405508 · Phase 3 · registry result, not featured evidence somnolence 34.6% (placebo 30.8%) dizziness 15.4% (placebo 15.4%) headache 7.7% (placebo 7.7%) NCT01405508 · Phase 3 · registry result, not featured evidence 100 mg/day headache 9% (placebo 10%) fatigue 8% (placebo 2%) somnolence 8% (placebo 6%) NCT00490035 · Phase 3 · registry result, not featured evidence 50 mg/day headache 18.2% (placebo 10%) dizziness 7.1% (placebo 5%) somnolence 6.1% (placebo 6%) NCT00490035 · Phase 3 · registry result, not featured evidence 20 mg/day headache 14.1% (placebo 10%) nasopharyngitis 8.1% (placebo 1%) somnolence 8.1% (placebo 6%) NCT00490035 · Phase 3 · registry result, not featured evidence 50 mg/day somnolence 16.8% (placebo 7.1%) dizziness 15.8% (placebo 9.2%) headache 12.9% (placebo 14.3%) NCT00464269 · Phase 3 · registry result, not featured evidence 20 mg/day dizziness 14% (placebo 9.2%) somnolence 14% (placebo 7.1%) fatigue 13% (placebo 2%) NCT00464269 · Phase 3 · registry result, not featured evidence 5 mg/day somnolence 14.4% (placebo 7.1%) dizziness 12.4% (placebo 9.2%) headache 11.3% (placebo 14.3%) NCT00464269 · Phase 3 · registry result, not featured evidence headache 14.5% (placebo 19.8%) somnolence 11.1% (placebo 4.1%) dizziness 8.6% (placebo 5.8%) NCT00504881 · Phase 3 · registry result, not featured evidence somnolence 7.7% upper respiratory tract infection 7.7% aggression 0% NCT03405714 · Phase 2 · registry result, not featured evidence dizziness 16.7% pharyngitis 8.3% aggression 0% NCT03405714 · Phase 2 · registry result, not featured evidence ear infection 15.4% pyrexia 15.4% somnolence 15.4% NCT03405714 · Phase 2 · registry result, not featured evidence fatigue 8.3% insomnia 8.3% pruritus 8.3% NCT03405714 · Phase 2 · registry result, not featured evidence 100 mg dizziness 20% headache 13.3% nausea 13.3% NCT03021018 · Phase 2 · registry result, not featured evidence 200 mg nausea 13.3% dizziness 6.7% gamma-glutamyltransferase increased 6.7% NCT03021018 · Phase 2 · registry result, not featured evidence irritability 8.1% somnolence 8.1% decreased appetite 7.1% NCT00422422 · Phase 2 · registry result, not featured evidence 50 mg/day dizziness 7.7% (placebo 5.6%) fatigue 5.8% (placebo 3.7%) somnolence 5.8% (placebo 7.4%) NCT00175825 · Phase 2 · registry result, not featured evidence 20 mg/day somnolence 5.8% (placebo 7.4%) fatigue 3.8% (placebo 3.7%) headache 3.8% (placebo 7.4%) NCT00175825 · Phase 2 · registry result, not featured evidence 5 mg/day headache 8% (placebo 7.4%) influenza 8% (placebo 7.4%) neutropenia 8% (placebo 1.9%) NCT00175825 · Phase 2 · registry result, not featured evidence somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Brivaracetam
show 21 more results
show 1 more result
+ 34 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brivaracetam's landscape · Levetiracetam (Elepsia XR)'s landscape